SCHEMBL9903004

SCHEMBL9903004

COc1ccc2nccc(Oc3ccc(C(N)=O)cc3F)c2c1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.56
MET P08581 9/20 0.53
AXL P30530 4/20 0.53
MERTK Q12866 1/20 0.53
DDR2 Q16832 1/20 0.52
LMNA P02545 1/20 0.48
KDR P35968 4/20 0.47
AURKA O14965 3/20 0.47
TEK Q02763 3/20 0.47
AURKB Q96GD4 3/20 0.47
MAPK1 P28482 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
PDGFRA P16234 2/20 0.45
PDGFRB P09619 1/20 0.45
ABL1 P00519 1/20 0.44
LCK P06239 1/20 0.44
LYN P07948 1/20 0.44
FGFR2 P21802 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14967176 0.91 MET (0.57) KDM4EMETKDRAURKATEK
SCHEMBL3794835 0.86 MET (0.59) METAXLKDRPDGFRAPDGFRB
SCHEMBL4575945 0.83 MET (0.52) METAXLKDRPDGFRAFGFR2
SCHEMBL29812263 0.82 AXL (0.52) KDM4EMETAXLDDR2LMNA
SCHEMBL9903011 0.82 AXL (0.52) KDM4EMETAXLDDR2LMNA
SCHEMBL17361401 0.80 MET (0.55) METAXLMERTKKDRPDGFRA
SCHEMBL14967697 0.80 FLT3 (0.54) METAXLMERTKKDRAURKA
SCHEMBL14966992 0.79 FLT3 (0.58) METAXLKDRPDGFRAPDGFRB
SCHEMBL1591160 0.79 AXL (0.60) METAXLMERTKDDR2KDR
SCHEMBL26317961 0.79 KDM4E (0.55) KDM4EMETAXLMERTKDDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2462117-B1 QUINOLINYLOXYPHENYLSULFONAMIDES MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS E V (DE) 2017-06-28 EP disclosed
US-9169241-B2 Quinolinyloxyphenylsulfonamides MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2015-10-27 US disclosed
US-20140336191-A1 QUINOLINYLOXYPHENYLSULFONAMIDES MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2014-11-13 US disclosed
US-20120277231-A1 QUINOLINYLOXYPHENYLSULFONAMIDES MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2012-11-01 US disclosed
EP-2462117-A1 QUINOLINYLOXYPHENYLSULFONAMIDES Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2012-06-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140336191-A1 QUINOLINYLOXYPHENYLSULFONAMIDES TP53, AQP1, KRAS KDM4E 3979/4885MET 2187/4885AXL 4326/4885
US-20120277231-A1 QUINOLINYLOXYPHENYLSULFONAMIDES TP53, AQP1, KRAS KDM4E 3979/4885MET 2187/4885AXL 4326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.